Cargando…
Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with Schizophrenia
This study aims to confirm the initial pharmacogenetic finding observed within the clinical proof-of-concept trial of an enhanced response to treatment with pomaglumetad methionil (LY2140023 monohydrate) in Caucasian schizophrenia patients homozygous for T/T at single nucleotide polymorphism rs73304...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810388/ https://www.ncbi.nlm.nih.gov/pubmed/26861400 http://dx.doi.org/10.3390/jpm6010009 |
_version_ | 1782423801415335936 |
---|---|
author | Nisenbaum, Laura K. Downing, AnnCatherine M. Zhao, Fangyi Millen, Brian A. Munsie, Leanne Kinon, Bruce J. Adams, David H. Gomez, Juan Carlos Penny, Michelle Ann |
author_facet | Nisenbaum, Laura K. Downing, AnnCatherine M. Zhao, Fangyi Millen, Brian A. Munsie, Leanne Kinon, Bruce J. Adams, David H. Gomez, Juan Carlos Penny, Michelle Ann |
author_sort | Nisenbaum, Laura K. |
collection | PubMed |
description | This study aims to confirm the initial pharmacogenetic finding observed within the clinical proof-of-concept trial of an enhanced response to treatment with pomaglumetad methionil (LY2140023 monohydrate) in Caucasian schizophrenia patients homozygous for T/T at single nucleotide polymorphism rs7330461 in the serotonin (5-hydroxytryptamine) 2A receptor gene compared to A/A homozygous patients. The effect of the rs7330461 genotype on the response to pomaglumetad methionil treatment was assessed in three additional clinical trials and in an integrated analysis. Overall, this study includes data from 1115 Caucasian patients for whom genotyping information for rs7330461 was available, consisting of 513 A/A homozygous, 466 A/T heterozygous and 136 T/T homozygous patients. Caucasian T/T homozygous patients showed significantly (p ≤ 0.05) greater improvement in Positive and Negative Syndrome Scale (PANSS) total scores during treatment with pomaglumetad methionil 40 mg twice daily compared to A/A homozygous patients. Additionally, T/T homozygous patients receiving pomaglumetad methionil had significantly (p ≤ 0.05) greater improvements in PANSS total scores compared to placebo and similar improvements as T/T homozygous patients receiving standard-of-care (SOC) treatment. The findings reported here in conjunction with prior reports show that in Caucasian patients with schizophrenia, the T/T genotype at rs7330461 is consistently associated with an increased treatment response to pomaglumetad methionil compared to the A/A genotype. |
format | Online Article Text |
id | pubmed-4810388 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-48103882016-04-04 Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with Schizophrenia Nisenbaum, Laura K. Downing, AnnCatherine M. Zhao, Fangyi Millen, Brian A. Munsie, Leanne Kinon, Bruce J. Adams, David H. Gomez, Juan Carlos Penny, Michelle Ann J Pers Med Article This study aims to confirm the initial pharmacogenetic finding observed within the clinical proof-of-concept trial of an enhanced response to treatment with pomaglumetad methionil (LY2140023 monohydrate) in Caucasian schizophrenia patients homozygous for T/T at single nucleotide polymorphism rs7330461 in the serotonin (5-hydroxytryptamine) 2A receptor gene compared to A/A homozygous patients. The effect of the rs7330461 genotype on the response to pomaglumetad methionil treatment was assessed in three additional clinical trials and in an integrated analysis. Overall, this study includes data from 1115 Caucasian patients for whom genotyping information for rs7330461 was available, consisting of 513 A/A homozygous, 466 A/T heterozygous and 136 T/T homozygous patients. Caucasian T/T homozygous patients showed significantly (p ≤ 0.05) greater improvement in Positive and Negative Syndrome Scale (PANSS) total scores during treatment with pomaglumetad methionil 40 mg twice daily compared to A/A homozygous patients. Additionally, T/T homozygous patients receiving pomaglumetad methionil had significantly (p ≤ 0.05) greater improvements in PANSS total scores compared to placebo and similar improvements as T/T homozygous patients receiving standard-of-care (SOC) treatment. The findings reported here in conjunction with prior reports show that in Caucasian patients with schizophrenia, the T/T genotype at rs7330461 is consistently associated with an increased treatment response to pomaglumetad methionil compared to the A/A genotype. MDPI 2016-02-05 /pmc/articles/PMC4810388/ /pubmed/26861400 http://dx.doi.org/10.3390/jpm6010009 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Nisenbaum, Laura K. Downing, AnnCatherine M. Zhao, Fangyi Millen, Brian A. Munsie, Leanne Kinon, Bruce J. Adams, David H. Gomez, Juan Carlos Penny, Michelle Ann Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with Schizophrenia |
title | Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with Schizophrenia |
title_full | Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with Schizophrenia |
title_fullStr | Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with Schizophrenia |
title_full_unstemmed | Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with Schizophrenia |
title_short | Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with Schizophrenia |
title_sort | serotonin 2a receptor snp rs7330461 association with treatment response to pomaglumetad methionil in patients with schizophrenia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810388/ https://www.ncbi.nlm.nih.gov/pubmed/26861400 http://dx.doi.org/10.3390/jpm6010009 |
work_keys_str_mv | AT nisenbaumlaurak serotonin2areceptorsnprs7330461associationwithtreatmentresponsetopomaglumetadmethionilinpatientswithschizophrenia AT downinganncatherinem serotonin2areceptorsnprs7330461associationwithtreatmentresponsetopomaglumetadmethionilinpatientswithschizophrenia AT zhaofangyi serotonin2areceptorsnprs7330461associationwithtreatmentresponsetopomaglumetadmethionilinpatientswithschizophrenia AT millenbriana serotonin2areceptorsnprs7330461associationwithtreatmentresponsetopomaglumetadmethionilinpatientswithschizophrenia AT munsieleanne serotonin2areceptorsnprs7330461associationwithtreatmentresponsetopomaglumetadmethionilinpatientswithschizophrenia AT kinonbrucej serotonin2areceptorsnprs7330461associationwithtreatmentresponsetopomaglumetadmethionilinpatientswithschizophrenia AT adamsdavidh serotonin2areceptorsnprs7330461associationwithtreatmentresponsetopomaglumetadmethionilinpatientswithschizophrenia AT gomezjuancarlos serotonin2areceptorsnprs7330461associationwithtreatmentresponsetopomaglumetadmethionilinpatientswithschizophrenia AT pennymichelleann serotonin2areceptorsnprs7330461associationwithtreatmentresponsetopomaglumetadmethionilinpatientswithschizophrenia |